Nature

Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both ...

Idiopathic myelofibrosis (IMF) is a chronic myeloproliferative disorder characterized by bone marrow fibrosis, extramedullary hematopoiesis, splenomegaly, anemia and peripheral blood ...
Business Wire

Promedior Announces Completion of Patient Enrollment Milestones in Phase 2 Clinical Studies of PRM-151 in Both Idiopathic Pulmonary Fibrosis and Myelofibrosis

The idiopathic pulmonary fibrosis (IPF) trial completed the enrollment of 117 patients while the myelofibrosis trial completed enrollment of 84 patients. Promedior plans to present the results of ...
Business Insider

Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., March 26, 2019 /PRNewswire/ -- Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that PRM-151, a ...
GEN

EC Clears First Myelofibrosis Drug

Novartis’ Jakavi® (ruxolitinib, INC424) has become the first drug to be approved by the EC for treating myelofibrosis. Regulatory clearance in Europe covers use of the JAK1/2 inhibitor for treating ...
WFMZ-TV

Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche

LEXINGTON, Mass., Nov. 15, 2019 /PRNewswire/ -- Promedior, Inc., today announced that it has entered into a definitive merger agreement for Roche (SIX: RO, ROG; OTCQX: RHHBY) to acquire Promedior.
The Globe and Mail

Primary Myelofibrosis Pipeline 2025: Pioneering Clinical Developments by 55+ Global Leaders – DelveInsight | Featuring Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma ...

DelveInsight’s, “Primary myelofibrosis- Pipeline Insight, 2025” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Primary myelofibrosis pipeline landscape. It covers ...
Mena FN

Primary Myelofibrosis Pipeline 2025: Pioneering Clinical Developments By 55+ Global Leaders Delveinsight Featuring Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology

"Primary Myelofibrosis Pipeline 2025"DelveInsight's,“Primary myelofibrosis- Pipeline Insight, 2025” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Primary ...